Department of Medical Imagings, Hematology and Oncology, Ribeirão Preto Medical School, University of São Paulo (FMRP-USP), Ribeirão Preto, Brazil.
Latin America Cooperative Oncology Group (LACOG), Porto Alegre, Brazil.
Head Neck. 2023 Oct;45(10):2505-2514. doi: 10.1002/hed.27470. Epub 2023 Aug 9.
Compare outcomes after surgery (S) or radiotherapy (RT) for T1a-T1b glottic squamous cell carcinoma (T1GSCC) in a population-based cohort study.
Patients diagnosed with T1GSCC from 1999 to 2020 were identified from a public database. Clinical, demographic, and social data were extracted. Treatment and patient groups and subgroups were compared with log-rank test, Cox proportional test, and propensity-score matched (PSM).
Eight hundred and eighty-eight patients with T1GSCC were included in the study, with a median follow-up of 61 months. The 5- and 10-year overall survival (OS) S versus RT were 76% versus 71% and 60% versus 52% (p = 0.02), respectively. In the subgroup analysis, S was associated with better OS for T1b, male, and public service patients (p < 0.05). In the PSM cohort of S versus RT with 110 patients each, there was no significant difference in the OS, CSS, and LC.
T1GSCC has favorable outcomes with S or RT.
在基于人群的队列研究中比较 T1a-T1b 声门型鳞状细胞癌（T1GSCC）患者接受手术（S）或放疗（RT）后的结局。
从公共数据库中确定 1999 年至 2020 年期间诊断为 T1GSCC 的患者。提取临床、人口统计学和社会数据。采用对数秩检验、Cox 比例风险检验和倾向评分匹配（PSM）比较治疗和患者组及亚组。
本研究纳入 888 例 T1GSCC 患者，中位随访时间为 61 个月。S 组与 RT 组的 5 年和 10 年总生存率（OS）分别为 76%比 71%和 60%比 52%（p=0.02）。亚组分析显示，T1b、男性和公共服务患者 S 治疗的 OS 更好（p<0.05）。在 S 与 RT 的 PSM 队列中，每组各有 110 例患者，OS、CSS 和 LC 无显著差异。
S 或 RT 治疗 T1GSCC 结局良好。
